A
Andreas Festa
Researcher at Eli Lilly and Company
Publications - 64
Citations - 11053
Andreas Festa is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Diabetes mellitus & Insulin resistance. The author has an hindex of 40, co-authored 62 publications receiving 10594 citations. Previous affiliations of Andreas Festa include University of Texas Health Science Center at San Antonio & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome The Insulin Resistance Atherosclerosis Study (IRAS)
Andreas Festa,Ralph B. D'Agostino,George Howard,Leena Mykkänen,Russell P. Tracy,Steven M. Haffner +5 more
TL;DR: In this article, the relation of C-reactive protein (CRP), fibrinogen, and white cell count to components of the insulin resistance syndrome (IRS) in the nondiabetic population of the Insulin Resistance Atherosclerosis Study (IRAS) (n=1008; age, 40 to 69 years; 33% with impaired glucose tolerance), was investigated.
Journal ArticleDOI
Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study
TL;DR: Chronic inflammation emerges as a new risk factor for the development of type 2 diabetes; PAI-1 predicts type 1 diabetes independent of insulin resistance and other known risk factors for diabetes.
Journal ArticleDOI
The relation of body fat mass and distribution to markers of chronic inflammation.
Andreas Festa,Ralph B. D'Agostino,Ken Williams,Andrew J. Karter,Elizabeth J. Mayer-Davis,Russell P. Tracy,S. M. Haffner +6 more
TL;DR: Findings show that measures of body fat are strongly associated with circulating levels of CRP and fibrinogen, and chronic, subclinical inflammation may be one pathophysiological mechanism explaining the increased risk of atherosclerotic disease associated with adiposity.
Journal ArticleDOI
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
M. A. Nauck,S. Duran,Dennis Kim,Don Johns,Justin Northrup,Andreas Festa,R. Brodows,Michael E. Trautmann +7 more
TL;DR: Exenatide treatment resulted in HbA1c reduction similar to biphasic insulin aspart and provided better postprandial glycaemic control, making it a potential alternative for the treatment of type 2 diabetes.
Journal ArticleDOI
Insulin-Resistant Prediabetic Subjects Have More Atherogenic Risk Factors Than Insulin-Sensitive Prediabetic Subjects Implications for Preventing Coronary Heart Disease During the Prediabetic State
TL;DR: The data suggest that atherogenic changes in the prediabetic state are mainly seen in insulin-resistant subjects and that strategies to prevent type 2 diabetes might focus on insulin-sensitizing interventions rather than interventions that increase insulin secretion because of potential effects on cardiovascular risk.